Clinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
NCT03229278 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
- Lead sponsor
- Rutgers, The State University of New Jersey
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 3, 2017
- Completion date
- October 30, 2022
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lymphoma, metastatic malignant solid neoplasm, metastatic melanoma, metastatic renal cell cancer, recurrent bladder carcinoma, recurrent classical hodgkin lymphoma, recurrent head and neck squamous cell carcinoma, recurrent lymphoma, recurrent malignant solid neoplasm, recurrent renal cell carcinoma, stage iii bladder cancer, stage iii lymphoma, stage iii non-small cell lung cancer ajcc v7, stage iii renal cell cancer, stage iii skin melanoma, stage iiia non-small cell lung cancer ajcc v7, stage iiia skin melanoma, stage iiib non-small cell lung cancer ajcc v7, stage iiib skin melanoma, stage iiic skin melanoma, stage iv bladder cancer, stage iv lymphoma, stage iv non-small cell lung cancer ajcc v7, stage iv renal cell cancer, stage iv skin melanoma, stage iva bladder cancer, stage ivb bladder cancer, unresectable head and neck squamous cell carcinoma, unresectable solid neoplasm